Toll Free: 1-888-928-9744

Tinea pedis (Athlete Foot) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tinea pedis (Athlete Foot) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tinea pedis (Athlete Foot) - Pipeline Review, H2 2016, provides an overview of the Tinea pedis (Athlete Foot) (Infectious Disease) pipeline landscape.

Athlete's foot, also known as tinea pedis, is a common foot infection caused by fungi called dermatophytes. Symptoms include dry flaking skin on the soles of the feet, unpleasant foot odour and small itchy bubbles or blisters on the soles of the feet. Treatment includes antifungal medicines. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tinea pedis (Athlete Foot) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Tinea pedis (Athlete Foot) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tinea pedis (Athlete Foot) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tinea pedis (Athlete Foot) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 3 and 1 respectively.

Tinea pedis (Athlete Foot) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Tinea pedis (Athlete Foot) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Tinea pedis (Athlete Foot) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tinea pedis (Athlete Foot) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tinea pedis (Athlete Foot) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Tinea pedis (Athlete Foot) (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tinea pedis (Athlete Foot) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tinea pedis (Athlete Foot) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Tinea pedis (Athlete Foot) Overview 6 Therapeutics Development 7 Pipeline Products for Tinea pedis (Athlete Foot) - Overview 7 Tinea pedis (Athlete Foot) - Therapeutics under Development by Companies 8 Tinea pedis (Athlete Foot) - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Tinea pedis (Athlete Foot) - Products under Development by Companies 12 Tinea pedis (Athlete Foot) - Companies Involved in Therapeutics Development 13 Anacor Pharmaceuticals Inc 13 Astellas Pharma Inc 14 Biolab Farmaceutica Ltda 15 Blueberry Therapeutics Ltd 16 Dermala Inc 17 Helix BioMedix Inc 18 Novan Inc 19 Novoteris LLC 20 Sol-Gel Technologies Ltd 21 Viamet Pharmaceuticals Inc 22 Tinea pedis (Athlete Foot) - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 AN-2718 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 AS-2077715 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 BB-2603 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 dapaconazole - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Drug for Athlete's Foot - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 E-06 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 HB-1275 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 nitric oxide - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 SB-208 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 VT-1161 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Tinea pedis (Athlete Foot) - Dormant Projects 45 Tinea pedis (Athlete Foot) - Product Development Milestones 46 Featured News & Press Releases 46 Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program 46 Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting 46 Jul 09, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Studies of VT-1161 with Moderate to Severe Interdigital Tinea Pedis 47 Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161 47 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 49 Disclaimer 50
List of Tables
Number of Products under Development for Tinea pedis (Athlete Foot), H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Comparative Analysis by Early Stage Development, H2 2016 11 Products under Development by Companies, H2 2016 12 Tinea pedis (Athlete Foot) - Pipeline by Anacor Pharmaceuticals Inc, H2 2016 13 Tinea pedis (Athlete Foot) - Pipeline by Astellas Pharma Inc, H2 2016 14 Tinea pedis (Athlete Foot) - Pipeline by Biolab Farmaceutica Ltda, H2 2016 15 Tinea pedis (Athlete Foot) - Pipeline by Blueberry Therapeutics Ltd, H2 2016 16 Tinea pedis (Athlete Foot) - Pipeline by Dermala Inc, H2 2016 17 Tinea pedis (Athlete Foot) - Pipeline by Helix BioMedix Inc, H2 2016 18 Tinea pedis (Athlete Foot) - Pipeline by Novan Inc, H2 2016 19 Tinea pedis (Athlete Foot) - Pipeline by Novoteris LLC, H2 2016 20 Tinea pedis (Athlete Foot) - Pipeline by Sol-Gel Technologies Ltd, H2 2016 21 Tinea pedis (Athlete Foot) - Pipeline by Viamet Pharmaceuticals Inc, H2 2016 22 Assessment by Monotherapy Products, H2 2016 23 Number of Products by Stage and Target, H2 2016 25 Number of Products by Stage and Mechanism of Action, H2 2016 27 Number of Products by Stage and Route of Administration, H2 2016 29 Number of Products by Stage and Molecule Type, H2 2016 31 Tinea pedis (Athlete Foot) - Dormant Projects, H2 2016 45



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify